Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Clinical Trial

Multicenter Study

Review

Publication Year

From

Quick links

Individual year

2016

2015

2014

2013

2012

2009

2007

2006

2002

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Lipoproteins, HDL3""[mesh_terms]

11 Results

Searching titles within these results

Antiatherogenic small, dense HDL--guardian angel of the arterial wall?

Anatol Kontush, M John Chapman

Nature clinical practice. Cardiovascular medicine 2006;3(3):144-53

Full Text

Abstract

Chemical modification of high density lipoprotein subfractions - HDL2 and HDL3 - after use of atorvastatin.

Vanessa Helena de Souza Zago, José Eduardo Tanus-Santos, Mirian Regina Gardin Danelon, Eliane Soler Parra, Fernanda Alexandre, Isabela Calanca Vieira, Natália Baratella Panzoldo, Fábio Luís D'Alexandri, Eder Carlos Rocha Quintão, Eliana Cotta de Faria

International journal of clinical pharmacology and therapeutics 2014;52(4):277-83

Full Text

Abstract

Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.

Elise F Villard, Maryse Guerin, Cécile Goujard, Corinne Vigouroux, Laurence Meyer, Patrick Yeni, Caroline Lascoux-Combe, Wilfried Le Goff, Mathilde Ghislain, Petra El Khoury

Journal of lipid research 2015;56(3):692-702

Free Full Text

Abstract

α-Tocopherol induces proatherogenic changes to HDL2 & HDL3: an in vitro and ex vivo investigation.

Nida Nadeem, Lauren Wade, Cyril McMaster, Jayne V Woodside, Ann McGinty, Ian S Young, Jane McEneny

Atherosclerosis 2013;226(2):392-7

Full Text

Abstract

Increased high-density lipoprotein-3 binding to leukocytes following weight loss and improved glycemic control in type 2 diabetic patients.

J A Paniagua, J López-Miranda, S Jansen, J L Zambrana, F López Segura, J A Jiménez Perepérez, F Pérez-Jiménez

Metabolism: clinical and experimental 2000;49(6):692-7

Full Text

Abstract

Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.

J H J M Meuwissen, L Beijers-De Bie, T Vihtamaki, R Tuimala, N Siseles, C Magaril, H S The, P W H Houben, M Murga, D Spielmann, T J De Villiers

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2002;16(2):155-62

Full Text

Abstract

Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux.

Angela Pirillo, Patrizia Uboldi, Gianluca Pappalardo, Hartmut Kuhn, Alberico L Catapano

Cardiovascular research 2007;75(3):566-74

Free Full Text

Abstract

Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3.

Boris Hansel, Xavier Girerd, Dominique Bonnefont-Rousselot, Randa Bittar, Sandrine Chantepie, Alexina Orsoni, Eric Bruckert, M John Chapman, Anatol Kontush

American journal of cardiovascular drugs : drugs, devices, and other interventions 2012;11(5):317-25

Full Text

Abstract

Serum- and HDL3-serum amyloid A and HDL3-LCAT activity are influenced by increased CVD-burden.

Peter McKavanagh, Jane McEneny, Edmund York, Patrick M Donnelly, Gareth J McKay, Ian S Young, Thomas Trinick, Lisa Lusk, Peter Ball, Michael Stevenson, Mark Harbinson, Nida Nadeem

Atherosclerosis 2016;244():172-8

Free Full Text

Abstract

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.

Enrico P Veltri, Bo Yang, Ramachandran Suresh, Alexandre P LeBeaut, Leslie J Lipka, J Frederick McNeer, Mark P Ettinger, Carlos A Dujovne

The American journal of cardiology 2002;90(10):1092-7

Full Text

Abstract

The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia.

D P Mikhailidis, E S Nakou, T D Filippatos, A D Tselepis, D N Kiortsis, M S Elisaf, C S Derdemezis

Expert opinion on pharmacotherapy 2009;9(18):3151-8

Full Text

Abstract

Results: 1 – 11 / 11

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Lipoproteins, HDL3""[mesh_terms]

Antiatherogenic small, dense HDL--guardian angel of the arterial wall?

Chemical modification of high density lipoprotein subfractions - HDL2 and HDL3 - after use of atorvastatin.

Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.

α-Tocopherol induces proatherogenic changes to HDL2 & HDL3: an in vitro and ex vivo investigation.

Increased high-density lipoprotein-3 binding to leukocytes following weight loss and improved glycemic control in type 2 diabetic patients.

Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.

Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux.

Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3.

Serum- and HDL3-serum amyloid A and HDL3-LCAT activity are influenced by increased CVD-burden.

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.

The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia.

Results for
""Lipoproteins, HDL3""[mesh_terms]